长春高新：子公司注射用GenSci143注册临床试验申请获受理

Core Viewpoint - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GenSci143, a dual-specific antibody-drug conjugate targeting B7-H3 and PSMA, indicating potential dual therapeutic effects in chemotherapy and tumor immunotherapy [1] Company Summary - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, is advancing its drug development with the acceptance of the clinical trial application for GenSci143 [1] - GenSci143 is a self-developed drug by Changchun Jinsai Pharmaceutical, showcasing the company's commitment to innovative cancer therapies [1] Industry Summary - The acceptance of GenSci143's clinical trial application highlights the growing focus on dual-targeting therapies in the oncology sector, particularly those that combine chemotherapy and immunotherapy [1]